BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of ProlivTMRx System for MDD

AI Briefing

• – BrainsWay completes $6M investment in Neurolief following FDA approval of ProlivTMRx system for MDD.
• – BrainsWay's investment was triggered by FDA Premarket Approval for Neurolief's Proliv TM Rx system.
• – Proliv TM Rx system is for mental health disorders.